The International Ultmann Chicago Lymphoma Symposium (IUCLS) is an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
We are fortunate to have a multitude of the world’s experts in lymphoma speak each year at the conference. The audience is comprised of regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that includes five academic centers. Next year’s program offered in 2019 represents the 16th IUCLS.
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. The format of the meeting includes a combination of expert presentations, interactive case discussions, poster/abstract presentations, and an opportunity for question-and-answer debates. The IUCLS is a two-day meeting held Friday afternoon and Saturday morning and early afternoon. Friday afternoon concentrates on the scientific and translational aspects of lymphoma, while Saturday has a clinical focus.
Learn more at the symposium website!
Target Audience
This activity is designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists and the other healthcare professionals interested in the treatment and diagnosis of lymphoma.
Learning Objectives
At the conclusion of this educational activity, participants will be able to:
· Distinguish between the different treatment approaches for newly diagnosed T-cell lymphoma and mantle cell lymphoma;
· Discuss the role of allogeneic stem cell transplant in Hodgkin lymphoma treatment;
· Identify patient characteristics best suited for CAR T-cell treatment;
· Differentiate between the different lymphoma staging and re-staging classifications to develop an appropriate patient treatment plan;
· Evaluate the different treatment options for follicular lymphoma and the risk of transformation to other cancers;
· State key environmental and genetics risks for lymphoma and the roles they play in lymphoid malignancies;
· Outline key molecular and cytogenetic information in order to determine best treatment options for chronic lymphocytic leukemia;
· Determine short and long-term toxicities of cardiotoxic agents used in lymphoma treatment;
· Describe how epigenetic targets in lymphoid cancers can be used to improve patient outcomes;
· List non-chemotherapy options for follicular lymphoma.
